New Data in the Treatment of METex14-skipping Advanced NSCLC
Clinical Insights on the Management of Edema Associated With MET Inhibitors in NSCLC
Please refer to the JAMA publication for the updates on the VISION trial: Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial
Comments 0
Login to view comments.
Click here to Login
